News|Articles|March 4, 2025
Optimizing next-generation sequencing for precision oncology trials
Author(s)Thermo Fisher Scientific
This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
uniQure and FDA Clash Over Regulatory Decision for Huntington’s Disease Therapy: Report
2
Eli Lilly Launches Employer Connect Platform Offering Obesity Coverage Options
3
From Approval to Access: 4 Steps to Rethinking Market Access Strategy in Specialty Pharma
4
Advancing Full-Spectrum Cannabis Through FDA
5